RxDoctor Payments Data

Debra Tooker, PA

Medical · Rogers, ARNPI 1164728739

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,670 of the $1,877 with a category attached, or 89.0%. It is spread thinly across 40 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations.

$1,877in general payments, 2019–2025

Across 99 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$272
  • Stemline Therapeutics Inc.$145
  • Regeneron Healthcare Solutions, Inc.$121
  • Pharmaessentia USA Corporation$121
  • Gilead$99
  • Genentech USA, Inc.$99
  • plus $1K from 34 others

What the payments were for

  • Food & beverage$1,67089%
  • Education$1438%
  • Other$643%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,877 in reported general payments places this provider in the 70th percentile of 133 medical providers in Arkansas.

See all medical providers in Arkansas

Medicare billing

Part B allowed, 2024
$5,343
Medicare patients
41
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ondansetron OdtOndansetron16$240

Paid to pharmacies, not to this prescriber.

Other medical in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →